Journal article
Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis
D Hanjaya-Putra, C Haller, X Wang, E Dai, B Lim, L Liu, P Jaminet, J Yao, A Searle, T Bonnard, CE Hagemeyer, K Peter, EL Chaikof
Jci Insight | AMER SOC CLINICAL INVESTIGATION INC | Published : 2018
Abstract
Despite advances in antithrombotic therapy, the risk of recurrent coronary/cerebrovascular ischemia or venous thromboembolism remains high. Dual pathway antithrombotic blockade, using both antiplatelet and anticoagulant therapy, offers the promise of improved thrombotic protection; however, widespread adoption remains tempered by substantial risk of major bleeding. Here, we report a dual pathway therapeutic capable of site-specific targeting to activated platelets and therapeutic enrichment at the site of thrombus growth to allow reduced dosing without compromised antithrombotic efficacy. We engineered a recombinant fusion protein, SCE5-TAP, which consists of a single-chain antibody (SCE5) t..
View full abstractGrants
Awarded by National Heart, Lung, and Blood Institute
Funding Acknowledgements
We thank Glenn Merrill-Skoloff (BIDMC Center for Hemostasis and Thrombosis Research Core) for assistance with IVM. We thank Shirley K. Wrobleski and Jose A. Diaz (Conrad Jobst Vascular Research Laboratories, University of Michigan) for training assistance in the EIM of venous thrombosis. We acknowledge support from the NIH (R01HL128237) for ELC, the Juvenile Diabetes Research Foundation with Postdoctoral Fellowship (3-PDF2014-188-A-N) for DHP, the William Harvey Research Institute-Academy with Fellowship for TB, the National Heart Foundation of Australia for XW and CEH, and the National Health and Medical Research Council of Australia for KP.